Senolytic drugs restore motor cortex function in ALS mouse model
On September 18, Neurobiology of Disease, September 18 published a study from the University of Missouri showing that signs of cellular senescence appear early in the brains of mice carrying the TDP-43 Q331K mutation, before full ALS disease onset. The researchers used this mouse model to test whether removing senescent cells could alter disease progression.
Fifteen weeks of treatment with the senolytic combination dasatinib and quercetin (D&Q) — first tried in humans in 2019 for pulmonary fibrosis — was administered to a cohort of the mice. In earlier pilot studies in elderly people at
🔗 Read original →
PubMed Central (PMC)
Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies
Amyotrophic Lateral Sclerosis (ALS) is a group of sporadic and genetic neurodegenerative disorders that result in losses of upper and lower motor neurons. Treatment of ALS is limited, and survival is 2–5 years after disease onset. While ALS can ...
September 20, 2026 10
